Moderna nears COVID-19 vaccine finish line as it wraps up study enrolmentModerna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of Share XModerna nears COVID-19 vaccine finish line as it wraps up study enrolmenthttps://pharmaphorum.com/news/moderna-nears-covid-19-vaccine-finish-line-as-it-wraps-up-study-enrolment/
Adult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar Share XAdult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13https://pharmaphorum.com/news/adult-data-back-mercks-challenger-to-pfizers-blockbuster-prevnar-13/
Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedPfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at Share XPfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedhttps://pharmaphorum.com/news/pfizer-ready-to-roll-if-biontech-covid-19-shot-is-approved/
UK government signs contract for COVID-19 challenge trialThe UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will Share XUK government signs contract for COVID-19 challenge trialhttps://pharmaphorum.com/news/uk-government-signs-contract-for-covid-19-challenge-trial/
Pfizer to wait until after election to file COVID-19 vaccine in USPfizer said it will wait until after the US election to file its COVID-19 vaccine with the US Share XPfizer to wait until after election to file COVID-19 vaccine in UShttps://pharmaphorum.com/news/pfizer-to-wait-until-after-election-to-file-covid-19-vaccine-in-us/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Race for COVID-19 vaccine hots up as EMA begins review of BioNTech/Pfizer jabThe European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by Share XRace for COVID-19 vaccine hots up as EMA begins review of BioNTech/Pfizer jabhttps://pharmaphorum.com/news/ema-begins-rolling-review-biontech-pfizers-covid-19-shot/
Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in ChinaPfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration Share XPfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in Chinahttps://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
